Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 3499Neoplasms 2740Prostatic Neoplasms 1583Colorectal Neoplasms 1248Lung Neoplasms 1188Motor Activity 766Head and Neck Neoplasms 621Pancreatic Neoplasms 601Colonic Neoplasms 586Uterine Cervical Neoplasms 567Carcinoma, Non-Small-Cell Lung 560Carcinoma, Hepatocellular 559Rectal Neoplasms 516Stomach Neoplasms 493Brain Neoplasms 438Anxiety Disorders 401Ovarian Neoplasms 399Pain 376Esophageal Neoplasms 347Polycystic Ovary Syndrome 341Neoplasm Metastasis 340Fatigue 324Urinary Bladder Neoplasms 314Precursor Cell Lymphoblastic Leukemia-Lymphoma 303Melanoma 298Depression 286Multiple Myeloma 283Endometrial Neoplasms 263Lymphoma 258Hematologic Neoplasms 251

Interventions

dalpiciclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × OTHER × HR+/HER2- Advanced Breast Cancer × Clear all
NCT06711094 2024-12-02

Albumin-bound Paclitaxel、Dalpiciclib and AI in ER-Low (1%-10%) HER2-ABC

Fujian Medical University

Phase NA Not yet recruiting
52 enrolled
Breast

HR+/HER2- Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡